Otis Worldwide Corp (OTIS) Stock Price Today
Aura AI Summary
Key Stats
- $28.95BMarket Cap
- 3,271,506Volume
- IndustrialsSector
- $93.6252W High
- $64.0552W Low
- 67 DaysTypical Hold Time
- $36.78BEnterprise Value
- 2.31%Div Yield
- -Trading Activity
Track Otis Worldwide Corp (OTIS) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Otis Worldwide Corp has traded between a low of $64.05 and a high of $93.62, highlighting its annual price range. Buy and sell Otis Worldwide Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Most Recent News
Home Depot and Lowe's see declining sales amid high mortgage rates and weak housing market.
Home Depot and Lowe's reported declines in comparable transactions in Q3 2026 due to a sluggish housing market and rising mortgage rates now above 7%. This has led to fewer home sales and softer demand for home improvement projects, as consumers dela...

Tesla's Cybercab launch signals robotaxi growth in 2027, urging caution on a SpaceX merger before success.
Tesla has started selling Cybercabs, priced at $29,990 with a $299 monthly subscription, but their current use is limited to specific areas and lacks manual controls. This launch is mainly promotional, highlighting Tesla's focus on becoming a transpo...

FDA approval for Grail's Galleri cancer test expected in early 2027, key for insurer coverage and pricing.
Grail expects FDA approval for its multi-cancer early detection test, Galleri, in Q1 2027, which could lead to Medicare and commercial insurer coverage. Despite a failed primary endpoint in a large NHS trial, Galleri showed promising results for 12 d...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.